Holen Sie sich die Stockscreener-App
2.8693
2.76%
-0.0807
Schlusskurs vom Vortag:
$2.95
Offen:
$2.92
24-Stunden-Volumen:
364.48K
Relative Volume:
0.31
Marktkapitalisierung:
$187.60M
Einnahmen:
$488.00K
Nettoeinkommen (Verlust:
$-41.44M
KGV:
-3.0852
EPS:
-0.93
Netto-Cashflow:
$-31.47M
1W Leistung:
-5.95%
1M Leistung:
-12.81%
6M Leistung:
-8.06%
1J Leistung:
-35.68%
1-Tages-Spanne:
$2.79
$2.92
1-Wochen-Bereich:
$2.79
$3.28
52-Wochen-Spanne:
$2.01
$5.6395
Cardiff Oncology Inc Stock (CRDF) Company Profile
Firmenname
Cardiff Oncology Inc
Sektor
Branche
Telefon
858-952-7570
Adresse
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
Vergleichen Sie CRDF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.866 | 187.60M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.00 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.47 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.26 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.71 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
248.47 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-06 | Eingeleitet | Craig Hallum | Buy |
| 2022-01-05 | Eingeleitet | William Blair | Outperform |
| 2021-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-08-09 | Fortgesetzt | Maxim Group | Buy |
| 2020-10-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-10-08 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Cardiff Oncology Inc Aktie (CRDF) Neueste Nachrichten
Market Highlights: Cardiff Oncology Inc (CRDF) Ends on a High Note at 2.95 - DWinneX
Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Purchased by Geode Capital Management LLC - Defense World
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge - ADVFN
Cardiff Oncology Inc [CRDF] Records 50-Day SMA of $3.62 - knoxdaily.com
Market Insights: Cardiff Oncology Inc (CRDF)’s Notable Drop of -3.61, Closing at 2.94 - DWinneX
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
A Tale of Resilience: Cardiff Oncology Inc Amid Stock Market Turbulence - investchronicle.com
Cardiff Oncology (CRDF) Secures New U.S. Patent for Cancer Treatment Method | CRDF Stock News - GuruFocus
Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients - GlobeNewswire
A look into Cardiff Oncology Inc (CRDF)’s deeper side - Sete News
A closer look at Cardiff Oncology Inc (CRDF) is warranted - uspostnews.com
Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap touched US$186m last week, benefiting both individual investors who own 56% as well as institutions - simplywall.st
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial i - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing R - GuruFocus
Cardiff Wraps Up Enrollment in Phase 2 Trial of Prospective Colorectal Cancer Treatment - MarketScreener
Cardiff Oncology Announces Completion of Enrollment in Phase 2 C - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Cardiff Oncology (CRDF) Completes Enrollment for Phase 2 Trial in Colorectal Cancer | CRDF Stock News - GuruFocus
Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cardiff Oncology Completes Patient Enrollment in Phase 2 CRDF-004 Trial for RAS-Mutated Metastatic Colorectal Cancer, Additional Data Expected in 1H 2025 - Nasdaq
Cardiff Oncology Awards Strategic Compensation Package: Inside the Latest Employee Stock Options Grant - Stock Titan
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer - GlobeNewswire
Major Progress: First-line Colorectal Cancer Treatment Trial Hits Key Milestone - Stock Titan
Cardiff Oncology announces positive colorectal data and $40m stock oversubscription - MSN
Piper Sandler raises Cardiff Oncology stock target to $10 By Investing.com - Investing.com Canada
Raymond James Financial Inc. Takes Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
American Century Companies Inc. Raises Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Metastatic Prostate Cancer Market Future Business - openPR.com
HighTower Advisors LLC Grows Position in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Lucid Capital Markets sets $14 target on Cardiff Oncology stock By Investing.com - Investing.com Canada
Cardiff Oncology Inc (CRDF) Has A Gold Mine On Its Hands - stocksregister.com
Cardiff Oncology Inc [CRDF] Chief Financial Officer makes an insider purchase of 2,752 shares worth 14905.0. - knoxdaily.com
Charles Schwab Investment Management Inc. Sells 19,629 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
CRDF Shares Experience Decline in Value - knoxdaily.com
Is Cardiff Oncology, Inc. (CRDF) The Hot Biotech Stock Under $5? - Insider Monkey
Bank of New York Mellon Corp Increases Stock Holdings in Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is Cardiff Oncology 15% bump due to positive clinical trials or a short squeeze? - Mugglehead
Cardiff Oncology Inc (CRDF) Q4 2024 Earnings Report Preview: Wha - GuruFocus.com
Future Industry Growth Of Metastatic Prostate Cancer Market - openPR
Rhumbline Advisers Buys 10,290 Shares of Cardiff Oncology, Inc. (NASDAQ:CRDF) - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Cardiff Oncology’s Earnings Call: Optimism Amid Challenges - MSN
Financial Review: Kymera Therapeutics (NASDAQ:KYMR) vs. Cardiff Oncology (NASDAQ:CRDF) - Defense World
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy - Nasdaq
Q1 Earnings Forecast for CRDF Issued By William Blair - Defense World
Cardiff Oncology (NASDAQ:CRDF) Price Target Raised to $17.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Cardiff Oncology (NASDAQ:CRDF) Stock - MarketBeat
Cardiff Oncology Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Finanzdaten der Cardiff Oncology Inc-Aktie (CRDF)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cardiff Oncology Inc-Aktie (CRDF) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Levine James E. | Chief Financial Officer |
Dec 18 '24 |
Buy |
5.00 |
2,400 |
12,000 |
67,716 |
| Levine James E. | Chief Financial Officer |
Dec 16 '24 |
Buy |
3.83 |
2,564 |
9,820 |
62,564 |
| TANNENBAUM RENEE P | Director |
Dec 12 '24 |
Buy |
3.42 |
10,000 |
34,224 |
20,000 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
350,115 |
910,299 |
1,047,876 |
| PACE GARY W | Director |
Dec 11 '24 |
Buy |
2.60 |
11,500 |
29,900 |
1,059,376 |
1.36%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):